Meeting
2024 ASCO Genitourinary Cancers Symposium
A systematic review: Are the findings of indirect treatment comparisons (ITCs) in metastatic hormone-sensitive prostate cancer (mHSPC) consistent?
Authors
Neal D. Shore
Carolina Urologic Research Center, Myrtle Beach, SC
Neal D. Shore , Alicia K. Morgans , Noman Paracha , Sarah Hodgkinson , Christian Eichinger , Craig Millar , Stephanie Chen , Martin Boegemann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 324)
DOI
10.1200/JCO.2024.42.4_suppl.324
Abstract #
324
Poster Bd #
N15
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Treatment and survival of de novo metastatic prostate cancer in US veterans.
First Author: Martin W. Schoen
Poster
2023 ASCO Genitourinary Cancers Symposium
Oncologists’ perspectives on metastatic hormone sensitive prostate cancer management.
First Author: Patrick Heckman
Poster
2022 ASCO Annual Meeting
Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial.
First Author: Fred Saad
Poster
2018 Genitourinary Cancers Symposium
ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC).
First Author: Matthew Raymond Smith